← Leaderboards
William C Olson
Progenics Pharmaceuticals, Inc.
$17,385,230
Attributed
$17,385,230
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2005–12$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$33,791,539 · 17
By mechanism
U19$11,294,381 · 2
P01$8,477,510 · 3
R44$7,528,388 · 4
R43$3,697,097 · 6
R01$2,252,204 · 1
N01$541,959 · 1
Top collaborators
No co-investigators on record.
Most similar at Progenics Pharmaceuticals, Inc.
Same institution · by research overlap
- Nitya G Ray$3,938,575
- Dangshe Ma$5,789,789
- Gerald P Donovan$9,061,908
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsAntiaids AgentDrug Design /Synthesis /ProductionInnovationHiv InfectionsSuccessVaccinesBaseTechnologyDesignClinical ResearchDrug Screening /EvaluationHuman SubjectHiv Envelope Protein Gp120Hiv-1Human Immunodeficiency Virus 1Immune ResponseCd4 MoleculeAntigensProgramsAntibodiesGenerationsImmunogenicityGenetic
Grant awards (40)
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1,128,535
R01 · FY2012 · AI · contact PI
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1,123,669
R01 · FY2011 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$142,480
P01 · FY2011 · AI · contact PI
Administrative Core$142,480
P01 · FY2011 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,781,188
P01 · FY2010 · AI · contact PI
Trimer Production and Immunogenicity Testing$975,077
P01 · FY2010 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$414,799
U19 · FY2010 · AI · contact PI
Administrative Core$300,859
P01 · FY2010 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,860,535
P01 · FY2009 · AI · contact PI
Trimer Production and Immunogenicity Testing$975,915
P01 · FY2009 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$580,717
U19 · FY2009 · AI · contact PI
Administrative Core$298,976
P01 · FY2009 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$2,987,862
U19 · FY2008 · AI · contact PI
PSMA-VRP vaccine for prostate cancer$574,893
R44 · FY2008 · CA · contact PI
Core A - Administrative, Medical Regulatory, Biostatistics$549,604
U19 · FY2008 · AI · contact PI
Broadly Neutralizing MAbs against Hepatitis C Virus$287,309
R43 · FY2008 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$2,544,127
U19 · FY2007 · AI · contact PI
PSMA-VRP vaccine for prostate cancer$458,795
R44 · FY2007 · CA · contact PI
Broadly Neutralizing MAbs against Hepatitis C Virus$351,433
R43 · FY2007 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$3,028,502
U19 · FY2006 · AI · contact PI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$1,066,099
U19 · FY2005 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1,062,268
R44 · FY2005 · AI
Development of Small-Molecule HIV Entry Inhibitors$833,040
R44 · FY2005 · GM
PRO 542 Immunotherapy of Advanced HIV 1 Disease$291,376
R43 · FY2005 · AI
Core A Administrative, Medical, Regulatory, Biostatistics$122,671
U19 · FY2005 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1,034,766
R44 · FY2004 · AI
Transgenic Production of CD4-IgG2 for HIV Therapy$1,000,000
R44 · FY2004 · AI
PRO 542 Immunotherapy of Advanced HIV 1 Disease$300,000
R43 · FY2004 · AI
Transgenic Production of CD4-IgG2 for HIV Therapy$1,000,000
R44 · FY2003 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV$924,217
R44 · FY2003 · AI
Transgenic Production of CD4-IgG2 for HIV Therapy$640,409
R44 · FY2002 · AI
Development of Small-Molecule HIV Entry Inhibitors$300,276
R43 · FY2002 · GM
CCR5 Sulfopeptides:A New Class of HIV Entry Inhibitors$300,000
R43 · FY2002 · AI
Development of Small-Molecule HIV Entry Inhibitors$327,416
R43 · FY2001 · GM
PA 14 CORECEPTOR-TARGETED IMMUNOTHERAPY OF HIV INFECTION$300,067
R43 · FY2001 · AI
CCR5 Sulfopeptides:A New Class of HIV Entry Inhibitors$300,000
R43 · FY2001 · AI
TRANSGENIC PRODUCTION OF CD4-IGG2 FOR HIV THERAPY$300,000
R43 · FY2001 · AI
HIV VACCINE PRODUCTION$541,959
N01 · FY2000 · AI
PA 14 CORECEPTOR-TARGETED IMMUNOTHERAPY OF HIV INFECTION$339,220
R43 · FY2000 · AI
TRANSGENIC PRODUCTION OF CD4-IGG2 FOR HIV THERAPY$300,000
R43 · FY2000 · AI